Ann: Letter to Shareholders from the Board of Ave, page-35

re: Ann: Letter to Shareholders from the Boar... Worthind,

If ATC were taken to market 15 years ago, then it probably would be a bigger commercial success than Isentress, but it wasn't. It now finds itself well down the list (actually absent from the list) because its time has passed. It is really that simple. There are enough NRTI's out there and others aren't needed unless they are a significant improvement on the older ones.

Normally, you would see efficacy in 2b trials. ATC did not out perform 3TC there. In terms of phase III trials, you are right, the trial was cut short making it harder for ATC to be shown to be superior. But, at the end of the day, the data produced showed no significant difference for the primary endpoint. There is a reason we have primary endpoints, so I won't go into what was or wasn't shown in secondary endpoints.

Also, whether I hold or not is irrelevant. You are either take notice of what I say or you don't. No big deal.

For the record, I did briefly hold Avexa, but before they picked up ATC.

Bob